Lantus, a new long-acting BASAL insulin

The FDA just approved Lantus, a new long-acting BASAL insulin.

It's longer acting than NPH or Ultralente...and doesn't produce peak concentrations like other insulins.

Lantus is a synthetic insulin called insulin glargine. It differs from human insulin by 3 amino acids.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote